Compare F5 Inc (FFIV) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? F5 Inc trades at $460.11 (market cap $25.89B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: F5 Inc is far larger — about 3.1× Hinge Health Inc. Class A Common Stock's market cap, and F5 Inc is more actively traded (575,445 versus 1,624,526). Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FFIV | HNGE | |
|---|---|---|
Market Cap | $25.89B | $8.47B |
Volume | 575,445 | 1,624,526 |
Sector | Technology | Health |
52-Week High | $479.83 | $105.14 |
52-Week Low | $223.99 | $31.17 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $24.54B | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $476.24, up 0.58% today, showing strong momentum with three consecutive earnings beats and robust revenue growth to $3.09B in 2025. The stock exhibits bullish technical signals with moving averages supporting upward trends, while maintaining impressive profitability metrics including 81.87% gross margins and 21.95% net income margin. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight continued market positioning strength.
Despite trading above analyst consensus target of $416.60, FFIV demonstrates solid fundamentals with expanding margins and strategic AI partnerships. Key risks include valuation premium at 36.44 P/E ratio and competitive pressures in application security. Institutional interest remains strong with BlackRock's significant position, supporting medium-term growth prospects amid evolving cybersecurity demands.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
